State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; Tianjin Key Laboratory of Phytochemistry and Pharmaceutical Analysis, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
J Ethnopharmacol. 2022 Jan 30;283:114701. doi: 10.1016/j.jep.2021.114701. Epub 2021 Oct 1.
Xuanfei Baidu Decoction (XFBD), one of the "three medicines and three prescriptions" for the clinically effective treatment of COVID-19 in China, plays an important role in the treatment of mild and/or common patients with dampness-toxin obstructing lung syndrome.
The present work aims to elucidate the protective effects and the possible mechanism of XFBD against the acute inflammation and pulmonary fibrosis.
We use TGF-β1 induced fibroblast activation model and LPS/IL-4 induced macrophage inflammation model as in vitro cell models. The mice model of lung fibrosis was induced by BLM via endotracheal drip, and then XFBD (4.6 g/kg, 9.2 g/kg) were administered orally respectively. The efficacy and molecular mechanisms in the presence or absence of XFBD were investigated.
The results proved that XFBD can effectively inhibit fibroblast collagen deposition, down-regulate the level of α-SMA and inhibit the migration of fibroblasts. IL-4 induced macrophage polarization was also inhibited and the secretions of the inflammatory factors including IL6, iNOS were down-regulated. In vivo experiments, the results proved that XFBD improved the weight loss and survival rate of the mice. The XFBD high-dose administration group had a significant effect in inhibiting collagen deposition and the expression of α-SMA in the lungs of mice. XFBD can reduce bleomycin-induced pulmonary fibrosis by inhibiting IL-6/STAT3 activation and related macrophage infiltration.
Xuanfei Baidu Decoction protects against macrophages induced inflammation and pulmonary fibrosis via inhibiting IL-6/STAT3 signaling pathway.
宣肺败毒方（XFBD）是中国临床治疗 COVID-19 的“三药三方”之一，对湿毒郁肺证的轻症和/或普通患者的治疗发挥着重要作用。
本研究旨在阐明 XFBD 对急性炎症和肺纤维化的保护作用及可能机制。
我们使用 TGF-β1 诱导的成纤维细胞激活模型和 LPS/IL-4 诱导的巨噬细胞炎症模型作为体外细胞模型。采用 BLM 通过气管内滴注建立肺纤维化小鼠模型，然后分别给予 XFBD（4.6 g/kg，9.2 g/kg）口服给药。研究了有无 XFBD 时的疗效和分子机制。
结果证明，XFBD 能有效抑制成纤维细胞胶原沉积，下调α-SMA 水平，并抑制成纤维细胞的迁移。IL-4 诱导的巨噬细胞极化也受到抑制，包括 IL6、iNOS 在内的炎症因子的分泌也下调。在体内实验中，结果证明 XFBD 改善了小鼠的体重减轻和存活率。XFBD 高剂量给药组在抑制小鼠肺部胶原沉积和α-SMA 表达方面具有显著效果。XFBD 可通过抑制 IL-6/STAT3 激活及相关巨噬细胞浸润，减轻博来霉素诱导的肺纤维化。
宣肺败毒方通过抑制 IL-6/STAT3 信号通路，对巨噬细胞诱导的炎症和肺纤维化起到保护作用。
Zotero 插件
